Mubadala exits Arcadia minority stake; Bansk funds buy across US.

Mubadala Investment Company has divested its minority position in US-headquartered consumer health group Arcadia Consumer Healthcare, selling into a transaction led by investment vehicles managed by Bansk Group. The move completes Mubadala’s four-year growth partnership with the OTC and supplements platform.

Arcadia, known for a mix of over-the-counter and wellness brands, counts flagship products such as Nizoral, Colace, Senokot and CloSYS among its core portfolio. The business also markets names including Naturelo, Betadine and Kaopectate, a spread that positions Arcadia in the higher-margin segment of the global self-care market.

During Mubadala’s ownership, Arcadia’s top line expanded markedly: management reports that revenue tripled over the partnership period while profitability improved materially. Mubadala’s private equity director, Philip Yifei Bao, highlighted the firm’s role in accelerating organic growth and integrating acquisitions such as Avrio and CloSYS, saying Mubadala supported a strategic transformation of the platform.

The buyer is described as funds run by Bansk Group, with industry veteran Bart Becht serving as Senior Partner and Chairman of the acquiring group and Mike DeBiasi continuing in an operating leadership capacity within Arcadia. In public remarks, Mr Becht praised Mubadala’s long-term engagement and active stewardship as contributors to Arcadia’s expansion trajectory.

Market context underscores the rationale behind the deal. The combined North American OTC and premium supplements market remains attractive—analysts estimate the broader self-care category at tens of billions of dollars annually, with nutraceuticals and specialty OTC segments growing faster than consumer staples as ageing populations and preventive-health trends lift demand. Buyers have shown a willingness to pay for scale, trusted brand equity and distribution reach in recent deals across the space.

For Mubadala, the exit realises value from a multi-year growth play that emphasised buy-and-build and margin recovery. For Bansk, the acquisition adds a consolidated platform of clinically positioned and consumer-facing SKUs that can be expanded through distribution, innovation and cross-selling. The transaction sits within a wider pattern of mid-market buyouts in health and wellness, where trade and financial sponsors vie for differentiated brand portfolios.

Strategically, the transfer of the minority stake signals continued consolidation among specialist consumer-health investors and underlines investor appetite for asset-light, brand-led models with resilient cash flow. With new ownership in place, Arcadia is expected to press on with product development, international distribution and potential add-on acquisitions to deepen its presence in the OTC and supplements channels.